CFN Insider

CFN Insider explores how the U.S. cannabis industry is evolving and the potential impact of a DEA decision to reschedule the drug or its cannabinoid constituents with a leading market analyst and group of five legal experts. In addition, investment opportunities are identified that may arise from these changes. In this episode, we take a look at some of the latest developments: FDA Approves GW Pharma's Epidolex Impact on rescheduling cannabis and DEA's rescheduling possibilities (isolate vs. cannabis plant) Resulting investment plays (cannabinoid drug developers, hemp extracts) Legalization Roundtable: State cannabis programs are flourishing (on both coasts) and fairing well under the Trump Administration on a macro level in light of the Cole Memo rescission, but federal restraints persist Guests on the podcast include: Matt Karnes, Greenwave Advisors Rod Kight, Kight Law Seth Goldberg, Duane Morris LLP Silvia San Nichols, CEO of New Game Compliance Justin Hobson, Lane Powell

CFN Insider explores the branding principle in cannabis and how it's ever more critical with recreational legalization in California and soon in Canada while big national brands make inroads. Three experts from influential cannabis brands give us their insights. Featured Guests Jeffrey Britz, CEO of International Cannabrands Inc. (CSE: JUJU) Joe Hodas, CMO of GoFire, Formerly Dixie Brands CMO Dooma Wendschuh, CEO of Province Brands

CFN Insider looks at California's recreational market, which is poised to become the largest legal cannabis industry in the world. In addition, experts take a look at the elections earlier this month and how the results might impact the cannabis industry over the coming years. Featured Guests: Matt Karnes of Greenwave Advisors Sean Hocking of the Cannabis Law Report Eric Spitz of Golden Systems

The Cole Memo and other regulations have tried to open up banking access to the cannabis industry, but many banks and credit unions refuse to engage with the marijuana industry because it remains a Schedule I Controlled Substance. In this episode, we look at the challenges that cannabis businesses face and what's being done to solve the problem. Featured Guests Tyler Bäuerlein, VP Business Development at Hypur. Matt Karnes, Founder & CEO of GreenWave Advisors Tim Belvin, Founder of 420 Tech

The opioid epidemic has reached a critical point in the United States, with more than 60,000 Americans dying from overdose last year alone. In July 2017, opioid addiction was cited as the "FDA's biggest crisis" and CDC Director Thomas Frieden said "urgent action is critical". Cannabinoids, it turns out, could play a critical role in addressing the problem.

CFN Insider looks at where medical marijuana may be headed on a federal level and whether the industry has reached a critical mass. In addition, this episode looks at the status of legalization in other markets across North America and Europe. - What is the federal government's stance on medical marijuana? - Who is behind the opposition to medical marijuana? - What is the status of the cannabis industry in Europe? - Where are the best investment opportunities? Featured Guests - Matt Karnes of GreenWave Advisors - Stephen Murphy of Prohibition Partners